PMC:7309518 / 143-499 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"T7","span":{"begin":48,"end":51},"obj":"Disease"},{"id":"T8","span":{"begin":84,"end":102},"obj":"Disease"},{"id":"T9","span":{"begin":137,"end":145},"obj":"Disease"},{"id":"T10","span":{"begin":254,"end":257},"obj":"Disease"},{"id":"T11","span":{"begin":276,"end":284},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ct\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to thera"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":3,"end":12},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"}],"text":"ct\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to thera"}

{"project":"LitCovid-PubTator","denotations":[{"id":"7","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"8","span":{"begin":84,"end":102},"obj":"Disease"},{"id":"9","span":{"begin":137,"end":145},"obj":"Disease"},{"id":"15","span":{"begin":276,"end":284},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:C000657245"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:D001327"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:C000657245"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ct\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to thera"}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":3,"end":12},"obj":"Sentence"},{"id":"T6","span":{"begin":13,"end":237},"obj":"Sentence"},{"id":"T7","span":{"begin":239,"end":246},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ct\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to thera"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":84,"end":102},"obj":"Phenotype"},{"id":"T3","span":{"begin":156,"end":170},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002960"}],"text":"ct\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to thera"}